Key facts
- This page summarizes Steven H. Stein's Form 4 filing for Kura Oncology, Inc. (KURA).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 23 Jun 2022, 16:47.
Steven H. Stein - 21 Jun 2022 Form 4 Insider Report for Kura Oncology, Inc. (KURA)
- Reporting relationship
- Director
- Issuer ticker
- KURA
- Reported as of
- 21 Jun 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 23 Jun 2022, 16:47:55 UTC
- Prior SEC filing
- 21 Jan 2022
- Next SEC filing
- 30 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- Teresa Bair, Attorney-in-fact for Steven Stein
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Steven H. Stein filed Form 4 for Kura Oncology, Inc. (KURA) on 23 Jun 2022.
Change
- Previous filing in this sequence was filed on 21 Jan 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
KURA
transaction
Derivative
Option to purchase common stock
Award
- Transaction value
- $0
- Shares
- +23,000
- Change %
- Price
- $0.000000
- Shares after
- 23,000
- Date
- 21 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 23,000
- Exercise price
- $14.84
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
This option vests in full on the one year anniversary of the date of grant.